SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Andreas Samson who wrote (396)12/5/1997 8:17:00 PM
From: D Edwards  Read Replies (2) | Respond to of 9523
 
Andreas: Corrections to your post: MUSE is a trans-urethral delivery device which delivers a drug pellet of alpostadril (sp?) into the urethra. It is NOT topical but the delivery system (not the drug)is patented and marketed by VVUS. This drug is not necessarily a competitor to Viagra as the two drugs have been shown to be effective for different types of ED sufferers.

I believe it is HVSF that claims to have a topical ED drug but they have not made much progress in getting to market. Others can correct this statement if I am incorrect.

The Vivus MUSE system is on the market and reports are that they are selling as much as they can make.

Hope this clears up some misconceptions. I am long both PFE and VVUS.

Dave



To: Andreas Samson who wrote (396)12/6/1997 10:51:00 PM
From: BigKNY3  Respond to of 9523
 
The mode of action and administration for MUSE and Viagra are totally different.

Viagra will take over the "convenience" market segment within 6 months of its launch.. However, MUSE will have a niche for Viagra non-responders and maintainence of some current MUSE users in an expanding ED market.

BigKNY3


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News